Drug Insights

How to Effectively Search for Progesterone on Synapse

22 March 2024
2 min read

Progesterone, a diminutive molecule drug, acts as a modulator of the progesterone receptor (PR), exhibiting a broad spectrum of active indications. These encompass endometrial hyperplasia, female infertility, menstruation disturbances, habitual abortion, threatened abortion, amenorrhea, dysmenorrhea, infertility, metrorrhagia, and traumatic brain injuries. Interestingly, the identity of the entity responsible for its initial approval in January 1956 remains unknown. This medication is commonly employed to support pregnancy and has numerous gynecological applications. Depending on the indication, the route of administration can be oral, topical, or intravaginal. To summarize, progesterone is a versatile medication that has proven invaluable in addressing women's reproductive and gynecological issues, while also assisting the brain's recovery from injuries. Click on the image below to begin the exploration journey of Progesterone through the Synapse database!

图形用户界面, 应用程序

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Lynparza and Imfinzi Surpass Chemotherapy in Advanced Endometrial Cancer Response
Latest Hotspot
3 min read
Lynparza and Imfinzi Surpass Chemotherapy in Advanced Endometrial Cancer Response
22 March 2024
Lynparza and Imfinzi substantially increased the average response time, outperforming chemotherapy, in providing clinical advantages for individuals with advanced or relapsed endometrial cancer that shows proficient DNA mismatch repair.
Read →
What Is a Blockbuster Drug?
"What" Series
2 min read
What Is a Blockbuster Drug?
22 March 2024
A "blockbuster drug" is a term used in the pharmaceutical industry to describe a medication that is extremely successful in the market, generating significant sales and revenue.
Read →
Intellia Launches Phase 3 MAGNITUDE Trial for CRISPR Therapy NTLA-2001 in Cardiac Amyloidosis
Latest Hotspot
3 min read
Intellia Launches Phase 3 MAGNITUDE Trial for CRISPR Therapy NTLA-2001 in Cardiac Amyloidosis
22 March 2024
Intellia Therapeutics has revealed the initiation of their Phase 3 clinical trial named MAGNITUDE, where the first participant received a one-time CRISPR therapy, NTLA-2001, aimed at treating cardiac amyloidosis caused by transthyretin.
Read →
Your Ultimate Guide to Finding Glutathione on Synapse
Drug Insights
2 min read
Your Ultimate Guide to Finding Glutathione on Synapse
22 March 2024
Glutathione, a diminutive molecule drug, is a versatile medication used to treat a diverse range of medical conditions.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.